<DOC>
	<DOCNO>NCT00861926</DOCNO>
	<brief_summary>Double-blind , multinational , multicentre , randomize , 2-arm parallel-group study</brief_summary>
	<brief_title>Study Comparing Foster Efficacy Maintenance Reliever Versus Foster Maintenance + Salbutamol Reliever Asthmatics</brief_title>
	<detailed_description>To compare efficacy Foster maintenance therapy plus additional inhalation reliever Foster maintenance plus salbutamol reliever asthmatic</detailed_description>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Written sign date informed consent obtain . Male female patient age ≥ 18 year . A positive reversibility test Patients experience least one severe exacerbation 12 month entry ( last month ) Using inhaled corticosteroid ( ICS ) monotherapy use ICS fix free combination long act beta2 agonist ( LABA ) constant dose two month screen visit Not fully control asthmatic ( mean partly control or/and uncontrolled patient accord GINA guideline 2007 ) last month screen visit Forced expiratory volume first second ( FEV1 ) ≥ 60 % predicted patient normal value . Non smokers exsmokers Pregnant nursing ( lactate ) woman . Women childbearing potential UNLESS meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL use one acceptable method contraception Body Mass Index ( BMI ) &gt; 34 kg/m2 . Patient low respiratory tract infection affect patient 's asthma within 30 day screen visit . Use systemic steroid last month . Patients lung disease COPD , cystic fibrosis , interstitial lung disease clinically functionally significant lung disorder . Patients uncontrolled respiratory , haematological , immunologic , renal , neurologic , hepatic , endocrinal disease . Clinically relevant laboratory abnormality Patients abnormal QTcF interval value Intolerance contraindication treatment beta2agonists and/or ICS allergy component study treatment . Patients treat slowrelease corticosteroid 3 month prior screen visit . Patients treat antiIgE antibody . Patients treat LABA ICS/LABA fix combination 24h screen visit Severe asthma exacerbation last month screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Maintenance Reliever Treatments</keyword>
</DOC>